Cargando…
Differentiation of Bone Marrow Mesenchymal Stem Cells to Cardiomyocyte-Like Cells Is Regulated by the Combined Low Dose Treatment of Transforming Growth Factor-β1 and 5-Azacytidine
Bone marrow mesenchymal stem cells (BMMSCs) are used in cardiac tissue engineering for the regeneration of diseased hearts. We examined the differentiation of rat BMMSCs into cardiomyocyte-like cells when induced with a combined low dose treatment of transforming growth factor-β1 (TGF-β1) and 5-azac...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4677250/ https://www.ncbi.nlm.nih.gov/pubmed/26697074 http://dx.doi.org/10.1155/2016/3816256 |
_version_ | 1782405301299838976 |
---|---|
author | Shi, Shutian Wu, Xingxin Wang, Xiao Hao, Wen Miao, Huangtai Zhen, Lei Nie, Shaoping |
author_facet | Shi, Shutian Wu, Xingxin Wang, Xiao Hao, Wen Miao, Huangtai Zhen, Lei Nie, Shaoping |
author_sort | Shi, Shutian |
collection | PubMed |
description | Bone marrow mesenchymal stem cells (BMMSCs) are used in cardiac tissue engineering for the regeneration of diseased hearts. We examined the differentiation of rat BMMSCs into cardiomyocyte-like cells when induced with a combined low dose treatment of transforming growth factor-β1 (TGF-β1) and 5-azacytidine (5-AZA). Results showed that cell proliferation in the combined low dose treatment group of TGF-β1 and 5-AZA was increased compared with the TGF-β1 group or the 5-AZA group. The cell apoptosis was relieved by combined TGF-β1 and 5-AZA treatment compared to 5-AZA treatment alone. The number of cells positive for myosin heavy chain, connexin-43, α-actin, and troponin I in the combined treatment group was higher than those observed in the TGF-β1 group or the 5-AZA group. Moreover, the combined low dose treatment group of TGF-β1 and 5-AZA reveals the strongest expression of troponin I, α-actin, and phosphorylated extracellular signal-regulated protein kinases 1 and 2 (p-ErK1/2) among the treatment groups. These results suggest that the combined low dose treatment of TGF-β1 and 5-AZA can improve the differentiation potential of rat BMMSCs into cardiomyocyte-like cells and alleviate cell damage effects in vitro. The mechanism that is involved in influencing differentiation may be associated with p-ErK1/2. |
format | Online Article Text |
id | pubmed-4677250 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-46772502015-12-22 Differentiation of Bone Marrow Mesenchymal Stem Cells to Cardiomyocyte-Like Cells Is Regulated by the Combined Low Dose Treatment of Transforming Growth Factor-β1 and 5-Azacytidine Shi, Shutian Wu, Xingxin Wang, Xiao Hao, Wen Miao, Huangtai Zhen, Lei Nie, Shaoping Stem Cells Int Research Article Bone marrow mesenchymal stem cells (BMMSCs) are used in cardiac tissue engineering for the regeneration of diseased hearts. We examined the differentiation of rat BMMSCs into cardiomyocyte-like cells when induced with a combined low dose treatment of transforming growth factor-β1 (TGF-β1) and 5-azacytidine (5-AZA). Results showed that cell proliferation in the combined low dose treatment group of TGF-β1 and 5-AZA was increased compared with the TGF-β1 group or the 5-AZA group. The cell apoptosis was relieved by combined TGF-β1 and 5-AZA treatment compared to 5-AZA treatment alone. The number of cells positive for myosin heavy chain, connexin-43, α-actin, and troponin I in the combined treatment group was higher than those observed in the TGF-β1 group or the 5-AZA group. Moreover, the combined low dose treatment group of TGF-β1 and 5-AZA reveals the strongest expression of troponin I, α-actin, and phosphorylated extracellular signal-regulated protein kinases 1 and 2 (p-ErK1/2) among the treatment groups. These results suggest that the combined low dose treatment of TGF-β1 and 5-AZA can improve the differentiation potential of rat BMMSCs into cardiomyocyte-like cells and alleviate cell damage effects in vitro. The mechanism that is involved in influencing differentiation may be associated with p-ErK1/2. Hindawi Publishing Corporation 2016 2015-11-30 /pmc/articles/PMC4677250/ /pubmed/26697074 http://dx.doi.org/10.1155/2016/3816256 Text en Copyright © 2016 Shutian Shi et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Shi, Shutian Wu, Xingxin Wang, Xiao Hao, Wen Miao, Huangtai Zhen, Lei Nie, Shaoping Differentiation of Bone Marrow Mesenchymal Stem Cells to Cardiomyocyte-Like Cells Is Regulated by the Combined Low Dose Treatment of Transforming Growth Factor-β1 and 5-Azacytidine |
title | Differentiation of Bone Marrow Mesenchymal Stem Cells to Cardiomyocyte-Like Cells Is Regulated by the Combined Low Dose Treatment of Transforming Growth Factor-β1 and 5-Azacytidine |
title_full | Differentiation of Bone Marrow Mesenchymal Stem Cells to Cardiomyocyte-Like Cells Is Regulated by the Combined Low Dose Treatment of Transforming Growth Factor-β1 and 5-Azacytidine |
title_fullStr | Differentiation of Bone Marrow Mesenchymal Stem Cells to Cardiomyocyte-Like Cells Is Regulated by the Combined Low Dose Treatment of Transforming Growth Factor-β1 and 5-Azacytidine |
title_full_unstemmed | Differentiation of Bone Marrow Mesenchymal Stem Cells to Cardiomyocyte-Like Cells Is Regulated by the Combined Low Dose Treatment of Transforming Growth Factor-β1 and 5-Azacytidine |
title_short | Differentiation of Bone Marrow Mesenchymal Stem Cells to Cardiomyocyte-Like Cells Is Regulated by the Combined Low Dose Treatment of Transforming Growth Factor-β1 and 5-Azacytidine |
title_sort | differentiation of bone marrow mesenchymal stem cells to cardiomyocyte-like cells is regulated by the combined low dose treatment of transforming growth factor-β1 and 5-azacytidine |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4677250/ https://www.ncbi.nlm.nih.gov/pubmed/26697074 http://dx.doi.org/10.1155/2016/3816256 |
work_keys_str_mv | AT shishutian differentiationofbonemarrowmesenchymalstemcellstocardiomyocytelikecellsisregulatedbythecombinedlowdosetreatmentoftransforminggrowthfactorb1and5azacytidine AT wuxingxin differentiationofbonemarrowmesenchymalstemcellstocardiomyocytelikecellsisregulatedbythecombinedlowdosetreatmentoftransforminggrowthfactorb1and5azacytidine AT wangxiao differentiationofbonemarrowmesenchymalstemcellstocardiomyocytelikecellsisregulatedbythecombinedlowdosetreatmentoftransforminggrowthfactorb1and5azacytidine AT haowen differentiationofbonemarrowmesenchymalstemcellstocardiomyocytelikecellsisregulatedbythecombinedlowdosetreatmentoftransforminggrowthfactorb1and5azacytidine AT miaohuangtai differentiationofbonemarrowmesenchymalstemcellstocardiomyocytelikecellsisregulatedbythecombinedlowdosetreatmentoftransforminggrowthfactorb1and5azacytidine AT zhenlei differentiationofbonemarrowmesenchymalstemcellstocardiomyocytelikecellsisregulatedbythecombinedlowdosetreatmentoftransforminggrowthfactorb1and5azacytidine AT nieshaoping differentiationofbonemarrowmesenchymalstemcellstocardiomyocytelikecellsisregulatedbythecombinedlowdosetreatmentoftransforminggrowthfactorb1and5azacytidine |